Compare ITRG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRG | STTK |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 538.3M |
| IPO Year | 2017 | 2020 |
| Metric | ITRG | STTK |
|---|---|---|
| Price | $2.14 | $7.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.13 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.5M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $67.34 | N/A |
| Revenue Next Year | $25.89 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.43 | $0.71 |
| 52 Week High | $4.87 | $8.33 |
| Indicator | ITRG | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 59.92 |
| Support Level | $2.01 | $5.87 |
| Resistance Level | $2.98 | $7.69 |
| Average True Range (ATR) | 0.10 | 0.62 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 43.08 | 77.96 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.